3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Breast Neoplasms
3
Pancreatic Neoplasms
2
Pain, Postoperative
2
Agnosia
2
Vesico-Ureteral Reflux
1
Ureteral Neoplasms
1
Thymoma
1
Nephrolithiasis
1
Lymphedema
1
Lung Neoplasms
1
Liver Neoplasms
1
Leiomyoma
1
Laparoscopic Surgery
1
Kidney Neoplasms
1
Duodenal Neoplasms
1
Cerebrovascular Disorders
1
Interventions
Bevacizumab
9
pembrolizumab
5
lenvatinib
5
durvalumab
5
atezolizumab
5
tremelimumab
3
fludarabine
3
camrelizumab
3
apatinib
3
Ipilimumab
3
Cyclophosphamide
3
regorafenib
2
Riluzole
2
Radiotherapy
2
Nivolumab
2
Magnetic Resonance Imaging
2
Idarubicin
2
Blood Specimen Collection
2
Biopsy
2
yttrium chloride
1
trastuzumab deruxtecan
1
spartalizumab
1
sintilimab
1
pertuzumab
1
ferric carboxymaltose
1
epigallocatechin gallate
1
donafenib
1
cemiplimab
1
brodalumab
1
Yttrium-90
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Liver Neoplasms
×
Bupivacaine
×
Clear all
NCT03715517
2026-02-05
SAFER-L
University of Manitoba
Phase NA
Recruiting
128 enrolled